MRVI vs AZTA vs ILMN vs QGEN vs PACB

For growth investors, Qiagen N.

V. (QGEN) is the stronger pick with 5. 7% revenue growth year-over-year, versus -28. 3% for Maravai LifeSciences Holdings, Inc. (MRVI). Qiagen N. V. (QGEN) offers the better valuation at 16. 2x trailing P/E (13. 5x forward), making it the more compelling value choice. Analysts rate Maravai LifeSciences Holdings, Inc. (MRVI) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Qiagen N.

V. (QGEN) is the cheapest at 16. 2x versus Illumina, Inc. at 26. 0x. On forward P/E, Qiagen N. V. is actually cheaper at 13. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Qiagen N. V. wins at 0. 30x versus Illumina, Inc. 's 6. 43x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Qiagen N.

V. (QGEN) delivered a total return of -23. 1%, compared to -93. 9% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: AZTA returned +130. 4% versus PACB's -84. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Qiagen N.

V. (QGEN) is the lower-risk stock at 0. 40β versus Pacific Biosciences of California, Inc. 's 2. 41β — meaning PACB is approximately 495% more volatile than QGEN relative to the S&P 500. On balance sheet safety, Azenta, Inc. (AZTA) carries a lower debt/equity ratio of 6% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Qiagen N.

V. (QGEN) is pulling ahead at 5. 7% versus -28. 3% for Maravai LifeSciences Holdings, Inc. (MRVI). On earnings-per-share growth, the picture is similar: Qiagen N. V. grew EPS 436. 8% year-over-year, compared to -70. 1% for Pacific Biosciences of California, Inc.. Over a 3-year CAGR, PACB leads at 7. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Qiagen N.

V. (QGEN) is the more profitable company, earning 20. 3% net margin versus -341. 5% for Pacific Biosciences of California, Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QGEN leads at 24. 9% versus -348. 5% for PACB. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Qiagen N. V. (QGEN) is the more undervalued stock at a PEG of 0. 30x versus Illumina, Inc. 's 6. 43x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Qiagen N. V. (QGEN) trades at 13. 5x forward P/E versus 37. 0x for Azenta, Inc. — 23. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AZTA: 132. 4% to $44. 67.

In this comparison, QGEN (0.

8% yield) pays a dividend. MRVI, AZTA, ILMN, PACB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Qiagen N.

V. (QGEN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 40), 0. 8% yield). Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (QGEN: +63. 0%, PACB: -84. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MRVI is a small-cap quality compounder stock; AZTA is a small-cap quality compounder stock; ILMN is a mid-cap quality compounder stock; QGEN is a small-cap deep-value stock; PACB is a small-cap quality compounder stock. QGEN pays a dividend while MRVI, AZTA, ILMN, PACB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.